The Central Drug Standard Control Organization (CDSCO) has granted a waiver for local trial to extremely costly but very effective direct-acting antiviral drugs, which may make them almost ninety times cheaper than the USA. The official number of Hepatitis C patients in India is predicted to be about 12 million. India is now one of the few countries where generics are made available for interferon-free treatment.
The Central Drug Standard Control Organization (CDSCO) has granted a waiver for clinical trials for sofosbuvir and ledipasvir coformulations. The agency is also expected to bring generic versions of daclatasvir which are only imported at a huge price from other countries. The generic versions of daclatasvir are expected to cost only a fraction of what it costs now, whereas sofosbuvir and ledipasvir are expected to lead the Hepatitis C treatment due to their cost being slashed…
